Test ID SMAT Smooth Muscle Antibody Titer, Serum
Specimen Required
Only orderable as part of a reflex. For more information see SMAS / Smooth Muscle Antibody Screen, Serum.
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.8 mL
Collection Instructions: Centrifuge and aliquot serum into plastic vial
Secondary ID
608956Useful For
Antibody titer testing as a part of evaluating patients with chronic liver disease in whom the diagnosis of chronic active autoimmune hepatitis is suspected
Testing Algorithm
If the smooth muscle antibody (SMA) screen is equivocal or positive, then the SMA titer will be performed at an additional charge.
Method Name
Only orderable as part of a reflex. For more information see SMAS / Smooth Muscle Antibody Screen, Serum.
Indirect Immunofluorescence
Reporting Name
Smooth Muscle Ab Titer, SSpecimen Type
SerumSpecimen Minimum Volume
0.4 mL
Specimen Stability Information
Specimen Type | Temperature | Time | |
---|---|---|---|
Serum | Refrigerated (preferred) | 21 days | |
Frozen | 21 days |
Clinical Information
Autoimmune hepatitis (AIH) is caused by chronic inflammation within the liver, resulting in damage to the hepatocytes.(1) Initially, patients with AIH may be clinically asymptomatic, usually identified only through an incidental finding of abnormal liver function tests. At a more advanced stage, patients may manifest with symptoms such as jaundice, pruritus, or ascites, which are secondary to the more extensive liver damage. As implied by the name, AIH has many characteristics of an autoimmune disease, including female predominance, hypergammaglobulinemia, association with specific HLA alleles, responsiveness to immunosuppression, and the presence of autoantibodies. There are several autoantibodies associated with AIH, although the most common are smooth muscle antibodies (SMA). SMA are generally identified by indirect immunofluorescence using a smooth muscle substrate. The antigen specificity of SMA in the context of AIH has been identified as filamentous-actin (F-actin).(2) Because the clinical symptoms of AIH are nonspecific, being found in a variety of liver diseases (drug/alcohol-associated hepatitis, viral hepatitis, primary sclerosing cholangitis, etc), the diagnosis can be challenging. A set of diagnostic criteria for AIH has been published and includes the presence of various autoantibodies, elevated total IgG, evidence of hepatitis on liver histology, and absence of viral markers.(3) The combination of autoantibody serology, specifically SMA and anti-F-actin antibodies, with liver histology and thorough clinical evaluation are useful in the evaluation of patients with suspected autoimmune hepatitis.
Reference Values
Only orderable as part of a reflex. For more information see SMAS / Smooth Muscle Antibody Screen, Serum.
Negative
Reference values apply to all ages.
Cautions
Serologic tests for autoantibodies, including smooth muscle antibodies (SMA), should not be relied upon exclusively to determine the etiology or prognosis of patients with liver disease.
A positive result for SMA may occur in patients who do not have autoimmune hepatitis. A negative result does not exclude a diagnosis of autoimmune hepatitis.
Day(s) Performed
Monday through Saturday
Report Available
2 to 4 daysPerforming Laboratory

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86015